You have free access to this content

Cancer

Cover image for Cancer

1 July 2007

Volume 110, Issue 1

Pages 1–230

  1. Review Articles

    1. Top of page
    2. Review Articles
    3. Original Articles
    4. Correspondence
    1. You have free access to this content
      Merkel cell carcinoma: Critical review with guidelines for multidisciplinary management (pages 1–12)

      Christopher K. Bichakjian, Lori Lowe, Christopher D. Lao, Howard M. Sandler, Carol R. Bradford, Timothy M. Johnson and Sandra L. Wong

      Version of Record online: 22 MAY 2007 | DOI: 10.1002/cncr.22765

      • original image
      • original image
      • original image
      • original image
      • original image
      • original image
      • original image
      • original image
      • original image

      Merkel cell carcinoma is a rare cutaneous malignancy with an increasing incidence. In this review, the authors have provided a comprehensive reference, including treatment guidelines, based on the available evidence and their multidisciplinary experience.

    2. You have free access to this content
      Molecularly targeted therapy for malignant glioma (pages 13–24)

      Sith Sathornsumetee, David A. Reardon, Annick Desjardins, Jennifer A. Quinn, James J. Vredenburgh and Jeremy N. Rich

      Version of Record online: 22 MAY 2007 | DOI: 10.1002/cncr.22741

      • original image
      • original image

      Recent advances in neuro-oncology research have elucidated several molecular abnormalities underlying the pathogenesis of malignant glioma. In this review, the authors discuss the current understanding of molecular aberrations and the rational development of molecularly targeted therapies in malignant glioma.

  2. Original Articles

    1. Top of page
    2. Review Articles
    3. Original Articles
    4. Correspondence
    1. Disease Site

      Breast Disease
      You have free access to this content
      Non-Hodgkin lymphoma of the breast (pages 25–30)

      Kristen Ganjoo, Ranjana Advani, M. Rajan Mariappan, Alex McMillan and Sandra Horning

      Version of Record online: 31 MAY 2007 | DOI: 10.1002/cncr.22753

      • original image
      • original image
      • original image

      Primary lymphoma of the breast has been reported to have a high local and central nervous system recurrence (CNS) rate, suggesting the need for consolidation radiotherapy and CNS prophylaxis. A retrospective study was done to evaluate the institutional experience in this patient population.

    2. You have free access to this content
      Outcomes in patients with primary breast cancer and a subsequent diagnosis of endometrial cancer : Comparison of cohorts treated with and without tamoxifen (pages 31–37)

      Mandana Saadat, Pauline T. Truong, Hosam A. Kader, Caroline H. Speers, Eric Berthelet, Elissa McMurtrie and Ivo A. Olivotto

      Version of Record online: 17 MAY 2007 | DOI: 10.1002/cncr.22734

      • original image
      • original image
      • original image

      In this outcomes analysis of breast cancer patients who subsequently developed endometrial cancer, those who received tamoxifen were observed to have higher proportions of aggressive endometrial cancer subtypes but similar endometrial cancer-specific survival and overall survival compared with nontamoxifen patients.

    3. Endocrine Disease
      You have free access to this content
      Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid : A meta-analysis (pages 38–46)

      Ju-Han Lee, Eung-Seok Lee and Young-Sik Kim

      Version of Record online: 22 MAY 2007 | DOI: 10.1002/cncr.22754

      • original image
      • original image
      • original image
      • original image
      • original image
      • original image
      • original image
      • original image
      • original image
      • original image

      A meta-analysis aimed to assess the clinicopathologic significance of BRAF mutation in papillary thyroid carcinoma. The BRAF mutation was associated with histologic subtype, the presence of extrathyroidal extension, and advanced clinical stage, but not with ethnicity, age, sex, or tumor size.

    4. Gastrointestinal Disease
      You have free access to this content
      Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy (pages 47–55)

      Sunil Krishnan, Vishal Rana, Nora A. Janjan, Gauri R. Varadhachary, James L. Abbruzzese, Prajnan Das, Marc E. Delclos, Morris S. Gould, Douglas B. Evans, Robert A. Wolff and Christopher H. Crane

      Version of Record online: 30 MAY 2007 | DOI: 10.1002/cncr.22735

      • original image
      • original image
      • original image

      The results from this study indicated that, by excluding patients who have rapid, distant disease progression, induction chemotherapy may select patients with locally advanced pancreatic cancer for optimal benefit from consolidative chemoradiation therapy. The authors believe that this strategy of enriching the population of patients who receive a locoregional treatment modality merits prospective randomized evaluation.

    5. Genitourinary Disease
      You have free access to this content
      Prostate cancer-specific mortality after radical prostatectomy or external beam radiation therapy in men with 1 or more high-risk factors (pages 56–61)

      Anthony V. D'Amico, Ming-Hui Chen, William J. Catalona, Leon Sun, Kimberly A. Roehl and Judd W. Moul

      Version of Record online: 25 MAY 2007 | DOI: 10.1002/cncr.22737

      • original image
      • original image
      • original image
      • original image

      Men with a prostate-specific antigen velocity >2 ng/mL/year had a significantly higher risk of prostate cancer-specific mortality (PCSM) compared with men who had any other single high-risk factor. These men should be considered for randomized trials evaluating the impact on PCSM from adding systemic agents to standards of care for men with high-risk prostate cancer.

    6. You have free access to this content
      Micropapillary bladder cancer : A review of the University of Texas M. D. Anderson Cancer Center experience with 100 consecutive patients (pages 62–67)

      Ashish M. Kamat, Colin P. N. Dinney, Jason R. Gee, H. Barton Grossman, Arlene O. Siefker-Radtke, Pheroze Tamboli, Michelle A. Detry, Tracy L. Robinson and Louis L. Pisters

      Version of Record online: 31 MAY 2007 | DOI: 10.1002/cncr.22756

      • original image
      • original image
      • original image
      • original image

      Micropapillary bladder carcinoma is a variant of urothelial carcinoma and has a poor prognosis. Intravesical therapy appears to be ineffective in patients with this disease and those patients with surgically resectable disease should be offered early radical cystectomy.

    7. You have free access to this content
      Timing of biochemical failure and distant metastatic disease for low-, intermediate-, and high-risk prostate cancer after radiotherapy (pages 68–80)

      Peter B. Morgan, Alexandra L. Hanlon, Eric M. Horwitz, Mark K. Buyyounouski, Robert G. Uzzo and Alan Pollack

      Version of Record online: 22 MAY 2007 | DOI: 10.1002/cncr.22755

      • original image
      • original image
      • original image
      • original image

      The timing of biochemical failure and distant metastatic disease after radiotherapy for low-risk, intermediate-risk, and high-risk prostate cancer was determined. The patterns of failure suggest that the majority of early failures were due to subclinical micrometastases present at diagnosis, whereas late metastases at 10–12 years in every risk group were consistent with tumor spread from local persistence of disease.

    8. You have free access to this content
      Initial treatment patterns and outcome of contemporary prostate cancer patients with bone metastases at initial presentation : Data from CaPSURE (pages 81–86)

      Charles J. Ryan, Eric P. Elkin, Janet Cowan and Peter R. Carroll

      Version of Record online: 21 MAY 2007 | DOI: 10.1002/cncr.22736

      • original image
      • original image

      The current study utilized the CaPSURE registry to describe the natural history, initial treatment, and factors correlating with mortality in patients with bony metastatic disease (M+) at the time of initial presentation. Clinical and sociodemographic variables were analyzed to identify predictors of mortality. Of all patients studied, 2.4% were diagnosed with M+ disease; 84% received hormonal therapy within 6 months of diagnosis. Comorbid illness, young age at diagnosis, and cancer grade appear to negative affect disease-specific survival.

    9. Head and Neck
      You have free access to this content
      Promoter methylation as a common mechanism for inactivating E-cadherin in human salivary gland adenoid cystic carcinoma (pages 87–95)

      Chun-Ye Zhang, Li Mao, Lei Li, Zhen Tian, Xiao-Jian Zhou, Zhi-Yuan Zhang and Jiang Li

      Version of Record online: 22 MAY 2007 | DOI: 10.1002/cncr.22758

      • original image
      • original image
      • original image
      • original image
      • original image
      • original image
      • original image

      The authors examined the promoter methylation status and expression of E-cadherin in clinical specimens from 60 patients with salivary gland adenoid cystic carcinoma (ACC) and in 3 ACC cell lines. The results indicated that E-cadherin frequently is inactivated by promoter methylation in salivary gland ACC.

    10. Hematologic Malignancies
      You have free access to this content
      Hyperglycemia in patients with acute myeloid leukemia is associated with increased hospital mortality (pages 96–102)

      Naeem A. Ali, James M. O'Brien Jr, William Blum, John C. Byrd, Rebecca B. Klisovic, Guido Marcucci, Gary Phillips, Clay B. Marsh, Stanley Lemeshow and Michael R. Grever

      Version of Record online: 29 MAY 2007 | DOI: 10.1002/cncr.22777

      • original image
      • original image

      In a large cohort of patients with acute myeloid leukemia, subjects were at increased risk for mortality and for developing severe sepsis at even modest levels of hyperglycemia.

    11. You have free access to this content
      Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients (pages 103–111)

      Jonathan K. Armstrong, Georg Hempel, Susanne Koling, Linda S. Chan, Timothy Fisher, Herbert J. Meiselman and George Garratty

      Version of Record online: 21 MAY 2007 | DOI: 10.1002/cncr.22739

      • original image
      • original image
      • original image
      • original image

      Rapid clearance of poly(ethylene glycol)-asparaginase (PEG-ASNase) has been reported for up to one-third of patients treated for acute lymphoblastic leukemia. The presence of antibody specific to poly(ethylene glycol) was very closely associated with undetectable serum ASNase activity in PEG-ASNase-treated patients.

    12. You have free access to this content
      Immune reconstitution inflammatory syndrome in cancer patients with pulmonary aspergillosis recovering from neutropenia: Proof of principle, description, and clinical and research implications (pages 112–120)

      Marisa H. Miceli, Johan Maertens, Kristel Buvé, Monica Grazziutti, Gail Woods, Mazhar Rahman, Bart Barlogie and Elias J. Anaissie

      Version of Record online: 24 MAY 2007 | DOI: 10.1002/cncr.22738

      In patients with invasive pulmonary aspergillosis, clinical and radiologic worsening during neutrophil recovery may coincide with normalization of serum Aspergillus galactomannan values. In this setting, transient deterioration is caused by an immune reconstitution inflammatory syndrome—with aspergillosis response—and obviates the need for diagnostic and treatment modification. By contrast, persistently elevated galactomannan values indicate progressive aspergillosis, requiring changes in therapeutic strategy.

    13. You have free access to this content
      Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent follicular lymphoma (pages 121–128)

      Stefano Sacchi, Samantha Pozzi, Raffaella Marcheselli, Massimo Federico, Alessandra Tucci, Francesco Merli, Loretta Orsucci, Marina Liberati, Daniele Vallisa, Maura Brugiatelli and On behalf of the Italian Lymphoma Study Group (GISL)

      Version of Record online: 14 MAY 2007 | DOI: 10.1002/cncr.22740

      • original image
      • original image

      The current study was conducted to asses the safety profile and clinical activity of rituximab in combination with fludarabine and cyclophosphamide in patients with recurrent follicular lymphoma. This nonanthracycline-containing regimen, lasting up to 10 weeks, was found to be relatively well-tolerated and demonstrated significant antilymphoma activity with excellent clinical and/or molecular response rates.

    14. Hepatobiliary Disease
      You have free access to this content
      Repetitive short-course hepatic arterial infusion chemotherapy with high-dose 5-fluorouracil and cisplatin in patients with advanced hepatocellular carcinoma (pages 129–137)

      Jun Yong Park, Sang Hoon Ahn, Young Joon Yoon, Ja Kyung Kim, Hyun Woong Lee, Do Yun Lee, Chae Yoon Chon, Young Myoung Moon and Kwang-Hyub Han

      Version of Record online: 16 MAY 2007 | DOI: 10.1002/cncr.22759

      • original image
      • original image

      Hepatic arterial infusion chemotherapy with high-dose 5-fluorouracil (5-FU) and cisplatin given for 3 days achieved favorable results in patients with advanced hepatocellular carcinoma (HCC). Therefore, repetitive short-course hepatic arterial infusion chemotherapy with high-dose 5-FU and cisplatin may be useful as an alternative therapeutic option for patients with advanced HCC.

    15. Lung Disease
      You have free access to this content
      Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer (pages 138–147)

      Ji-Youn Han, Hyeong-Seok Lim, Yeon-Kyeong Yoo, Eun Soon Shin, Yong Hoon Park, Sung Young Lee, Jong-Eun Lee, Dea Ho Lee, Heung Tae Kim and Jin Soo Lee

      Version of Record online: 29 MAY 2007 | DOI: 10.1002/cncr.22760

      • original image
      • original image

      The authors investigated whether ABCB1 (1236C > T, 2677G > T/A, 3435C > T), ABCC2 (−24C > T, 1249G > A, 3972C > T), and ABCG2 (34G > A, 421C > A) polymorphisms affect pharmacokinetics (PK) of irinotecan and treatment outcome of patients with advanced NSCLC. When haplotypes are assigned by using 2677G > T/A and 3435C > T, homozygous 2677T/3435T carriers showed significantly lower AUCSN-38G (P = 0.006), whereas, homozygous 2677G/3435C carriers showed significantly higher AUCSN-38 (P = 0.039) and increasing tendency of AUCirinotecan (P = 0.068). These findings suggest that 2677TT and 3435TT variants are associated with higher efflux activity. The 2677G > T/A was associated with grade 4 neutropenia. The 2677GG carriers showed significantly lower absolute neutrophil count during the 1st cycle.

    16. You have free access to this content
      Stereotactic single-dose radiotherapy (radiosurgery) of early stage nonsmall-cell lung cancer (NSCLC) (pages 148–155)

      Holger Hof, Marc Muenter, Dieter Oetzel, Angelika Hoess, Juergen Debus and Klaus Herfarth

      Version of Record online: 21 MAY 2007 | DOI: 10.1002/cncr.22763

      • original image
      • original image
      • original image
      • original image
      • original image

      Stereotactic single-dose radiotherapy is a safe and effective treatment option for patients with early stage NSCLC not suitable for surgery. Especially for small tumor volumes it seems to be equally effective as hypofractionated radiotherapy, while minimizing overall treatment time.

    17. Neuro-Oncology
      You have free access to this content
      High-dose chemotherapy with autologous stem cell rescue followed by posterior fossa irradiation for local medulloblastoma recurrence or progression after conventional chemotherapy (pages 156–163)

      Vita Ridola, Jacques Grill, Francois Doz, Jean-Claude Gentet, Didier Frappaz, Marie-Anne Raquin, Jean-Louis Habrand, Christian Sainte-Rose, Dominique Valteau-Couanet and Chantal Kalifa

      Version of Record online: 31 MAY 2007 | DOI: 10.1002/cncr.22761

      • original image
      • original image
      • original image
      • original image
      • original image

      Young children with recurrent/progressive medulloblastoma after conventional chemotherapy were treated efficiently with high-dose chemotherapy plus hematopoietic stem cells transplantation followed by focal irradiation. Immediate toxicity was manageable, but worrisome delayed late effects on the irradiated central nervous system and on the gonads justify further therapeutic refinements.

    18. Sarcoma
      You have free access to this content
      Prognostic significance of CD100 expression in soft tissue sarcoma (pages 164–172)

      EweSeng Ch'ng, Yasuhiko Tomita, Binglin Zhang, Juxiang He, Yoshihiko Hoshida, Ying Qiu, Eiichi Morii, Itsuko Nakamichi, Ken-ichiro Hamada, Takafumi Ueda and Katsuyuki Aozasa

      Version of Record online: 22 MAY 2007 | DOI: 10.1002/cncr.22764

      • original image
      • original image

      The expression of CD100, a class IV semaphorin that promotes angiogenesis, invasive growth, proliferation, and antiapoptosis in soft tissue sarcoma (STS), and its correlation with prognosis were evaluated in 81 patients (47 men and 34 women) who ranged in age from 15 years to 89 years (median age, 54 years). CD100 expression proved to be an independent prognosticator and was useful in the stratification of high-risk patients with stage II and III STS according to the American Joint Committee on Cancer staging system. The manifold functions of CD100, both as a ligand and as a receptor, favor cell survival and proliferation; thus, the expression of CD100 may act as an indicator of malignant grade in cancers.

    19. You have free access to this content
      Primary angiosarcomas of the breast (pages 173–178)

      Taimur Sher, Bryan T. Hennessy, Vicente Valero, Krisitine Broglio, Wendy A. Woodward, Jonathan Trent, Kelly K. Hunt, Gabriel N. Hortobagyi and Ana M. Gonzalez-Angulo

      Version of Record online: 31 MAY 2007 | DOI: 10.1002/cncr.22784

      • original image
      • original image
      • original image

      A retrospective review is presented of the clinicopathologic characteristics and clinical outcomes of female patients with primary breast angiosarcoma.

    20. Discipline

      Pediatric Oncology
      You have free access to this content
      Resection alone in 58 children with limited stage, lymphocyte-predominant Hodgkin lymphoma–experience from the European network group on pediatric Hodgkin lymphoma (pages 179–185)

      Christine Mauz-Körholz, Stephanie Gorde-Grosjean, Dirk Hasenclever, Ananth Shankar, Wolfgang Dörffel, W. Hamish Wallace, Günther Schellong, Alain Robert, Dieter Körholz, Odile Oberlin, Georgina W. Hall and Judith Landman-Parker

      Version of Record online: 24 MAY 2007 | DOI: 10.1002/cncr.22762

      • original image
      • original image

      Lymphocyte-predominant Hodgkin lymphoma (LPHL) is a rare, CD20-positive, good prognostic lymphoma in children. Patients with early-stage LPHL who undergo successful surgical lymph node resection alone have been reported. To clarify the optimum treatment strategy in children, European study groups were asked to report their experience of surgery alone used in the treatment of pediatric LPHL.

    21. You have free access to this content
      Characteristics of pediatric chemotherapy medication errors in a national error reporting database (pages 186–195)

      Michael L. Rinke, Andrew D. Shore, Laura Morlock, Rodney W. Hicks and Marlene R. Miller

      Version of Record online: 25 MAY 2007 | DOI: 10.1002/cncr.22742

      Eighty-five percent of pediatric chemotherapy medication errors reach the patient, and 48% involve medication administration. Antimetabolites are involved 39.5% of the time, and methotrexate is involved specifically in 15.3% of errors.

    22. Symptom Control and Palliative Care
      You have free access to this content
      Interpreting clinically significant changes in patient-reported outcomes (pages 196–202)

      Jolie Ringash, Brian O'Sullivan, Andrea Bezjak and Donald A. Redelmeier

      Version of Record online: 1 JUN 2007 | DOI: 10.1002/cncr.22799

      • original image
      • original image

      One rule for interpreting a difference in quality-of-life scores is a benchmark of about 10% of the instrument range. Patients appear to be more sensitive to favorable differences, so an improvement of 5% may be meaningful.

    23. Translational Research
      You have free access to this content
      Overlapping human leukocyte antigen class I/II binding peptide vaccine for the treatment of patients with stage IV melanoma : Evidence of systemic immune dysfunction (pages 203–214)

      Melanoma Study Group of the Mayo Clinic Cancer Center and Esteban Celis

      Version of Record online: 31 MAY 2007 | DOI: 10.1002/cncr.22744

      • original image
      • original image
      • original image
      • original image
      • original image
      • original image

      The authors conducted a Phase II study of a glycoprotein 100-derived peptide vaccine for the treatment of patients with stage IV melanoma; and, although clinical outcomes were not improved as a result of immunization, the data demonstrated evidence of systemic cytokine overproduction leading to dendritic cell dysfunction and the emergence of T-cell tolerance to tumor antigens. Discussed are the implications of these findings for future therapeutic vaccine studies in advanced melanoma.

    24. You have free access to this content
      Reduced XPC messenger RNA level may predict a poor outcome of patients with nonsmall cell lung cancer (pages 215–223)

      Yi-Hui Wu, Ya-Wen Cheng, Jinghua Tsai Chang, Tzu-Chin Wu, Chih-Yi Chen and Huei Lee

      Version of Record online: 16 MAY 2007 | DOI: 10.1002/cncr.22743

      • original image
      • original image

      Kaplan-Meier analysis demonstrated that the median survival of patients with lower xeroderma pigmentosum complementary group C (XPC) mRNA levels was shorter compared with patients having higher XPC mRNA levels. Cox regression analysis further indicated that the XPC mRNA level may act as an independent prognostic factor for patients with nonsmall cell lung cancer (NSCLC). A reduced XPC mRNA level may constitute an independent prognostic factor for NSCLC patients.

  3. Correspondence

    1. Top of page
    2. Review Articles
    3. Original Articles
    4. Correspondence
    1. You have free access to this content
      Smaller regional volumes of gray and white matter demonstrated in breast cancer survivors exposed to adjuvant chemotherapy (pages 224–225)

      Michael H. R. Eichbaum, Andreas Schneeweiss and Christof Sohn

      Version of Record online: 14 MAY 2007 | DOI: 10.1002/cncr.22745

    2. You have free access to this content
      Author reply (page 225)

      Masatoshi Inagaki, Yosuke Uchitomi and Shigeru Imoto

      Version of Record online: 14 MAY 2007 | DOI: 10.1002/cncr.22746

    3. You have free access to this content
    4. You have free access to this content
      Author reply (pages 227–228)

      Barbara Goff

      Version of Record online: 7 MAY 2007 | DOI: 10.1002/cncr.22750

    5. You have free access to this content
      Predictive and discriminating three–risk–group prognostic scoring system for staging Hodgkin lymphomas (page 229)

      Luciana Britto, Nelson Spector and Adriana Scheliga

      Version of Record online: 8 MAY 2007 | DOI: 10.1002/cncr.22747

    6. You have free access to this content
      Author reply (page 230)

      Delphine Maucort-Boulch, Pierre Colonna and Jean-Marie Andrieu

      Version of Record online: 8 MAY 2007 | DOI: 10.1002/cncr.22748

SEARCH

SEARCH BY CITATION